RAINIER trial dose optimization for mipletamig continued; Aptevo also signed a 50/50 radiopharmaceutical collaboration with Niowave.
First-half financial results and cash position
Aptevo reported a net loss of $13.1 million for the six months ended June 30, 2026; operating cash outflow was $13.42 million.
Research and development spending rose to $7.62 million; mipletamig program costs increased to $3.95 million.
General and administrative expense was $5.7 million; other income increased to $0.2 million on higher interest income.
Cash and cash equivalents totaled $9.8 million at June 30, 2026; management said existing cash is not expected to fund operations for at least one year.
APVO•
